Auction One of the Rarest Breguet Watches to Headline Christie’s November Auction

A Significant Collection of Rare Watches to Be Auctioned in Support for Leukodystrophy Research

Christie’s Rare Watches auction is set to return to Geneva on November 11th at the prestigious Four Seasons Hotel des Bergues. Following the remarkable success of the May sale, which achieved a total of CHF 23 million, this season’s auction will showcase an array of rare and iconic models from esteemed brands such as Rolex, Patek Philippe, F.P. Journe, and Cartier, all meticulously curated for discerning collectors. Notably, a special segment of the auction will benefit the European Leukodystrophy Association (ELA), with eleven prominent brands—including Andersen Genève x BCHH, Bovet, Richard Mille, and Ulysse Nardin—donating timepieces to support research into leukodystrophies and assist affected families.

Among the remarkable pieces to be featured at the upcoming Rare Watches auction in November, Christie’s will present an exceptionally rare and historically significant timepiece: Breguet No. 3218. This tonneau-shaped perpetual calendar wristwatch, which includes a retrograde date and moon phases, was produced in 1935 and was originally sold to the celebrated French designer Paul Iribe. Known for his substantial contributions to Art Deco design, graphic arts, and Hollywood film sets.

The watch, signed Breguet, No. 3218, is described as “Quantième Perpétuel - date rétrograde, jours et mois guichets, phases de lune.” It was manufactured in 1935 and sold to Monsieur Paul Iribe on May 24, 1935, for the sum of 10,000 francs.  While the Estimate price now CHF 100,000 - 200,000.

Remi Guillemin, Head of Watches for Europe and the Americas, remarks: “Breguet No. 3218 is not only the earliest of the only two known Breguet perpetual calendar wristwatches featuring a retrograde date, but it also stands among the very few examples of vintage perpetual calendars from any brand.”

 

For more information, visit the official Christie's website.


0 Comments